Lacer

What Lacer does

Lacer, S.A. is a Barcelona-based pharmaceutical laboratory founded in 1949, organized into two divisions: Personal Health (over-the-counter medicines, cosmetics, and personal care products) and Prescription Medicines and Medical Devices. The Personal Health portfolio includes oral care brands (Lacer, GingiLacer, Sensilacer, Clorhexidina Lacer, Xerolacer, Ortolacer, Lacer Natur), hair and scalp care (Pilexil), dermatology (Talquistina, Balsoderm), peripheral circulation (Thrombocid, Thrombactiv), hemorrhoids (Anso, Ansollitas), allergy (Virlix Plus), and menopause supplements (Flavia). The Prescription division spans cardiovascular (Euradal, Kalpress, Lacerol, Lidaltrin, Uniket, Nitroplast, Secalip, Pantok, Roname, Ekistol), urology (Mictonorm), and gynecology (Adiaval, Intrarosa). Lacer develops formulations in-house at a GMP-certified manufacturing plant and \u20ac7 million R&D center at Parc Tecnol\u00f2gic del Vall\u00e8s in Cerdanyola del Vall\u00e8s.

The company operates a sales-led go-to-market: a direct pharmaceutical sales force (Delegado/a de Venta Farmacia) covers Spanish pharmacy territories with KAMs managing major retail accounts and trade marketing specialists executing point-of-sale activation. International expansion runs through a distributor network in 20+ countries across Latin America, Europe, the Middle East, and Asia Pacific, supported by EU Cosmetics and Japan Cosmetics certifications. Pricing follows a one-time/unit purchase model with PVP pricing in Spain; prescription medicines are partially reimbursed by the Spanish National Health System while OTC products are paid fully out of pocket by consumers. Lacer has held Pharmaceutical Laboratory Authorization 2718E from the Spanish Agency of Medicines since long-standing operation.

Since 2022, Lacer has operated as a subsidiary of Italian pharmaceutical group Grupo Italfarmaco, which acquired the company to reinforce group business areas and consolidate Lacer's leadership position in Spain. Lacer also maintains Efarmes, S.A. (established 1987), a wholly-owned subsidiary focused on development and licensing of generic medicines. The company has 251-500 employees and reports revenue streams across prescription, OTC, and medical device categories, though specific financial figures are not publicly disclosed.

Name

Lacer

Legal name

LACER, S.A.

Website

https://lacer.com

Company type

Private

Founded year

1949

Operating status

Operating

Headcount range

251–500 employees

Short description

Lacer is a Barcelona-based pharmaceutical laboratory founded in 1949, developing and manufacturing OTC personal care products and prescription medicines across oral health, hair care, dermatology, cardiovascular, urology, and gynecology for distribution through Spanish pharmacies and an international distributor network in 20+ countries.

Ownership category

akta.pro rank

Headquarters

HQ city

Barcelona

HQ country

Spain

HQ region

Europe

Offices2 records

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Prescription Medicines: Cardiovascular, urology, and gynecology prescription pharmaceuticals sold through pharmacies with National Health System reimbursement in Spain.
2. OTC and Personal Health Products: Over-the-counter medicines, cosmetics, and personal care products (oral health, hair care, dermatological) sold through pharmacy channel and international distributors.
3. Medical Devices: Medical devices including dental products (Lacerpro adhesive creams, Afta Lacer), sold through pharmacy and healthcare channels.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Core offering

Lacer is a pharmaceutical laboratory that develops, manufactures, and distributes prescription medicines (cardiovascular, urology, gynecology) and over-the-counter personal health products (oral care, hair care, dermatology, circulation, haemorrhoid care, muscle care, menopause support). The company sells primarily through Spanish pharmacies via its own sales force and reaches more than 20 international markets through distribution partnerships.

Product overview

Lacer is a pharmaceutical laboratory offering two main product divisions: Personal Health (OTC/cosmetics) and Prescription Medicines/Medical Devices. The Personal Health division includes oral care brands (Lacer, Gingilacer, Lacer Natur, Sensilacer, Clorhexidina Lacer, Xerolacer, Ortolacer), hair care (Pilexil), dermatology (Talquistina), circulatory products (Thrombocid), haemorrhoid treatments (Anso, Ansollitas), muscle care (Thrombactiv), sun care (Balsoderm), and menopause supplements (Flavia). The Prescription Medicines division covers cardiovascular treatments (Euradal, Kalpress, Lacerol, Lidaltrin, Uniket, Nitroplast, Secalip, Pantok, Roname, Ekistol), urology (Mictonorm), and gynecology (Adiaval, Intrarosa). All products are developed through the company's own R&D laboratory with over 50 years of experience.

Differentiator

Problem solved

Functional benefit

Brands

• LACER: Oral health products including toothpaste, toothgel, mouthwash, toothbrushes, electric toothbrushes, irrigators
• LACER NATUR
• GINGILACER
• LACER OROS
• SENSILACER
• CLORHEXIDINA LACER
• LACER BLANC
• LACER FRESH
• XEROLACER
• ORTOLACER
• LACERPRO
• AFTA LACER
• PILEXIL
• Thrombocid
• Thrombactiv
• Anso
• Ansollitas
• Talquistina
• BALSODERM
• VIRLIX PLUS
• Flavia

Products and services

• Lacer Oral Health Line Oral care product line including toothpaste, dental gel, mouthwash, manual toothbrushes, electric toothbrushes (Efficare), interdental brushes, dental floss, and oral irrigators with anticaries, antiplaque, and gum protection actions, sold through pharmacies to adult and child consumers.
• Lacer Natur

Quantifiable outcome

• Thrombocid has been on market for over 50 years as market leader in anti-varicose topical segment
• +5 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Grupo ItalfarmacocoreOthers · 1 January 2022Italian pharmaceutical laboratory Grupo Italfarmaco acquired Lacer in 2022. This acquisition allows reinforcing business areas and consolidating Lacer's leadership position in Spain. Lacer operates as part of the Italfarmaco Group, sharing resources, following Farmaindustria codes, and being supervised by the Spanish Agency of Medicines.

Scale indicators8 records

Recent moves8 records

Expansion highlights3 records

Direct peers

• Faes Farma: Spanish pharmaceutical laboratory with a comparable mix of prescription medicines, OTC and personal health/nutrition products, similar mid-cap profile, and strong pharmacy-channel presence in Spain and Latin America.
• Almirall: Barcelona-based pharmaceutical company operating across prescription dermatology and OTC/personal care categories with international distribution; closely comparable Spanish origin, pharmacy-led GTM, and mixed Rx/OTC portfolio.
• Laboratorios Rovi: Spanish pharmaceutical company with prescription and OTC products sold through pharmacy channels, including specialty and generics; comparable mid-cap Spanish pharma profile with international expansion.
• Uriach: Spanish family-owned pharmaceutical laboratory focused on OTC, personal care, and consumer health products distributed via pharmacies; directly comparable in OTC and personal health positioning.
• Grupo Italfarmaco: Italian pharmaceutical group that acquired Lacer in 2022; operates in prescription, OTC, and personal care across multiple geographies and serves as parent and strategic platform for Lacer.

Broad incumbents

• Menarini Group: Large Italian pharmaceutical group with broad OTC, consumer health, and prescription portfolio distributed across Europe, Latin America, and Asia; comparable in product mix and geographic model but at significantly greater scale.
• Angelini Pharma: Italian pharmaceutical company with consumer health, OTC, and prescription products across Europe; overlapping with Lacer in personal care/OTC categories and pharmacy distribution.
• Zambon: Italian pharmaceutical group active in prescription and consumer health across Europe and Latin America; comparable in mixed Rx/OTC model and cross-continental distribution.
• Recordati: European specialty pharmaceutical company with prescription and consumer health products; comparable in cardiovascular and urology prescription segments and in OTC presence.
• Bayer Consumer Health: Global OTC and personal care player whose consumer health division overlaps with Lacer's categories (oral care, skin care, cardiovascular prevention); competes for the same pharmacy shelf space and consumer mindshare.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/lacer/jobs
• Instagraminstagram.com/pilexil

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lacer